Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients with Treatment-Resistant Depression

Roy H. Perlis, Dan V. Iosifescu, Jonathan E. Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study assessed the effect of general medical comorbidity on response to next-step antidepressant treatments among subjects with major depressive disorder whose depression failed to respond to an 8-week open trial of 20 mg/ day of fluoxetine. Of the 386 outpatients in the open trial, 101 who remained depressed were randomly assigned to double-blind treatment with either an increased dose of fluoxetine or lithium or desipramine augmentation for 4 weeks. The Cumulative Illness Rating Scale (CIRS) was used to assess baseline general medical comorbidity, and the Hamilton Depression Rating Scale was used to assess depressive symptoms. Logistic regression analysis showed that CIRS score was not associated with likelihood of remission or premature study discontinuation. Medical comorbidity thus does not appear to be associated with significantly poorer outcome among patients whose major depressive disorder failed initially to respond to an initial trial of 20 mg/day of fluoxetine.

Original languageEnglish (US)
Pages (from-to)224-229
Number of pages6
JournalPsychosomatics
Volume45
Issue number3
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Fluoxetine
Comorbidity
Outpatients
Major Depressive Disorder
Depression
Desipramine
Lithium
Antidepressive Agents
Logistic Models
Regression Analysis
Therapeutics
Dose
Rating Scales
Augmentation
Illness

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this

Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients with Treatment-Resistant Depression. / Perlis, Roy H.; Iosifescu, Dan V.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: Psychosomatics, Vol. 45, No. 3, 05.2004, p. 224-229.

Research output: Contribution to journalArticle

Perlis, Roy H. ; Iosifescu, Dan V. ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients with Treatment-Resistant Depression. In: Psychosomatics. 2004 ; Vol. 45, No. 3. pp. 224-229.
@article{f50869cca9c341408b852d9775a57a21,
title = "Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients with Treatment-Resistant Depression",
abstract = "This study assessed the effect of general medical comorbidity on response to next-step antidepressant treatments among subjects with major depressive disorder whose depression failed to respond to an 8-week open trial of 20 mg/ day of fluoxetine. Of the 386 outpatients in the open trial, 101 who remained depressed were randomly assigned to double-blind treatment with either an increased dose of fluoxetine or lithium or desipramine augmentation for 4 weeks. The Cumulative Illness Rating Scale (CIRS) was used to assess baseline general medical comorbidity, and the Hamilton Depression Rating Scale was used to assess depressive symptoms. Logistic regression analysis showed that CIRS score was not associated with likelihood of remission or premature study discontinuation. Medical comorbidity thus does not appear to be associated with significantly poorer outcome among patients whose major depressive disorder failed initially to respond to an initial trial of 20 mg/day of fluoxetine.",
author = "Perlis, {Roy H.} and Iosifescu, {Dan V.} and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "2004",
month = "5",
doi = "10.1176/appi.psy.45.3.224",
language = "English (US)",
volume = "45",
pages = "224--229",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients with Treatment-Resistant Depression

AU - Perlis, Roy H.

AU - Iosifescu, Dan V.

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 2004/5

Y1 - 2004/5

N2 - This study assessed the effect of general medical comorbidity on response to next-step antidepressant treatments among subjects with major depressive disorder whose depression failed to respond to an 8-week open trial of 20 mg/ day of fluoxetine. Of the 386 outpatients in the open trial, 101 who remained depressed were randomly assigned to double-blind treatment with either an increased dose of fluoxetine or lithium or desipramine augmentation for 4 weeks. The Cumulative Illness Rating Scale (CIRS) was used to assess baseline general medical comorbidity, and the Hamilton Depression Rating Scale was used to assess depressive symptoms. Logistic regression analysis showed that CIRS score was not associated with likelihood of remission or premature study discontinuation. Medical comorbidity thus does not appear to be associated with significantly poorer outcome among patients whose major depressive disorder failed initially to respond to an initial trial of 20 mg/day of fluoxetine.

AB - This study assessed the effect of general medical comorbidity on response to next-step antidepressant treatments among subjects with major depressive disorder whose depression failed to respond to an 8-week open trial of 20 mg/ day of fluoxetine. Of the 386 outpatients in the open trial, 101 who remained depressed were randomly assigned to double-blind treatment with either an increased dose of fluoxetine or lithium or desipramine augmentation for 4 weeks. The Cumulative Illness Rating Scale (CIRS) was used to assess baseline general medical comorbidity, and the Hamilton Depression Rating Scale was used to assess depressive symptoms. Logistic regression analysis showed that CIRS score was not associated with likelihood of remission or premature study discontinuation. Medical comorbidity thus does not appear to be associated with significantly poorer outcome among patients whose major depressive disorder failed initially to respond to an initial trial of 20 mg/day of fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=2442506599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442506599&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.45.3.224

DO - 10.1176/appi.psy.45.3.224

M3 - Article

VL - 45

SP - 224

EP - 229

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 3

ER -